Drug intelligence / Profile preview

MRx109

Development stage: Preclinical
Lead developer: MyeloRx
Modality: Small Molecules

Overview

MRx109 is a small molecule immunosuppressant drug candidate with anti-fibrogenic properties. It is being developed by MyeloRx for the treatment of immune system diseases, specifically rheumatoid arthritis and organ transplant rejection (graft rejection). The drug acts as an immunosuppressant, aiming to modulate the immune response and reduce fibrosis. As of the latest updates, its highest development phase is preclinical[1][2].

Beyond the preview

Go deeper on MRx109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRx109.

Explore the full profile